Analytical Data
-
Gene name
CXCL14
- Application
-
Alternative Names
CXCL14；MIP2G；NJAC；SCYB14；C-X-C motif chemokine 14
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95715
-
Expression Region
35-111aa
-
AA Sequence
SKCKCS RKGPKIRYSD VKKLEMKPKY PHCEEKMVII TTKSVSRYRG QEHCLHPKLQ STKRFIKWYN AWNEKRRVYE E
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL14, also known as BRAK (B-Cell Recruitment Activator Kit), is a chemokine that plays a significant role in regulating immune responses and has been implicated in various pathological conditions, including cancer and inflammatory diseases. It primarily functions by attracting immune cells, such as dendritic cells and T lymphocytes, thus influencing the recruitment and activation of these cells in the tumor microenvironment. Recent studies have highlighted the dual role of CXCL14 in cancer, where it can exhibit tumor-suppressive properties by inhibiting tumor growth and metastasis, yet it may also facilitate tumor progression under certain conditions. This has sparked interest in its potential therapeutic applications, as CXCL14 could be harnessed for immunotherapy strategies. The production of recombinant CXCL14 protein allows for detailed investigations into its biochemical properties, signaling pathways, and interactions with immune cells. Furthermore, understanding the structure-function relationship of CXCL14 can provide insights into its mechanisms of action, paving the way for the development of novel interventions in diseases characterized by dysregulated immune responses. Ongoing research aims to elucidate the complex roles of CXCL14 in the immune landscape, with the hope of translating these findings into innovative therapeutic options that enhance immune responses against tumors or regulate chronic inflammation.
